A Phase 1 Study of SGR-2921 in People With Acute Myeloid Leukemia or Myelodysplastic Syndrome


Full Title

A First-in-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome


The purpose of this study is to find the best dose of SGR-2921 to treat blood cancers. The people in this study have acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that keeps growing after treatment.

SGR-2921 targets a protein called CDC7, which helps cancer cells survive and grow. By targeting CDC7, SGR-2921 may stop the protein from working, causing cancer cells to die. SGR-2921 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have AML or MDS that keeps growing even though you had treatment.
  • Have not taken any other anti-cancer medication within 2 weeks of taking SGR-2921.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID